China Medical System (0867.HK) Accelerating Development and Stepping to New Heights, Driven by Innovation
HONG KONG, Apr 05, 2021 - (ACN Newswire) - As the earnings season arrives, listed pharmaceutical companies are attracting much attention. China Medical System Holdings Limited (CMS, or Company) has released its annual results, with both revenue and profit higher than market expectations. According to its 2020 earnings results, turnover is up by 14.4% to RMB6.946 billion; net profit up by 30.7% to RMB2.556 billion; basic earnings per share up to RMB1.024, with a proposed final dividend of RMB0.20 per share.
In the past, influenced by expectations of the effects of China's centralized procurement policy and the Company's product transition, CMS's valuation in the capital market was once under pressure, but with the Company's strategic transformation from a CSO to an innovative pharmaceutical company, coupled with its own solid business growth, its share price has gained a significant increase in the past few months, but is still relatively low in the capital market. The Company's current dynamic P/E ratio is only about 13x, with a market value of HK$ 39.4 billion.